<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aldila Pratiwi</style></author><author><style face="normal" font="default" size="100%">Bagus Setyoboedi</style></author><author><style face="normal" font="default" size="100%">Citrawati D. K. Wungu</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Factors Affecting the Long-Term Protection Against Hepatitis B Immunization in Infancy: A Meta-Analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Hepatitis B antibodies</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis B vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunization</style></keyword><keyword><style  face="normal" font="default" size="100%">Infant.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">385-394</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; Hepatitis B virus (HBV) infection is a major global health issues and one of the most dangerous viral infections with a high mortality rate. Newborns and infant vaccination against chronic HBV infection are crucial for preventing mother-to-child transmission (MTCT). This study aimed to conduct a meta-analysis to investigate the factors affecting long-term protection against Hepatitis B Immunization in infancy. &lt;strong&gt;Material and Methods:&lt;/strong&gt; Our literature searches are from PubMed, Science Direct, Web of Science, and ProQuest publications between January 2000 and December 2021. The included literature assessed the risk of bias using the Newcastle Ottawa Quality Assessment Scale. We identify Hepatitis B surface antibodies (anti-HBs) ≥ 10 mIU/mL as being protective against HBV infection. The results are combined with a random effect or fixed effect model. &lt;strong&gt;Results: &lt;/strong&gt;Eighteen eligible observational studies with a total of 16,642 participants were included. Analysis of factors affecting long-term protection status by assessing anti-HBs titers showed significant results on several factors, including gestational age for anti-HBs titers (OR 2.5; 95% CI 1.62-3.85; p&amp;lt;0.0001), weight for age to anti-HBs titers (OR 1.36; 95% CI 1.06-1.75; p=0.02), length for age to anti-HBs titers (OR 0.01; 95% CI 0.01-0.02; p&amp;lt;0.00001), and immunization status based on the number of vaccine doses (4 doses vs 3 doses) to anti-HBs titers (p&amp;lt;0.00001). &lt;strong&gt;Conclusions: &lt;/strong&gt;Anti-HBs titers of hepatitis B immunization were significantly affected by gestational age, weight for age, length for age, and vaccine doses. Parents of newborns must be informed about basic immunization and provide adequate nutritional intake to the mother and babies to prevent HBV infection.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">385</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Aldila Pratiwi&lt;sup&gt;1&lt;/sup&gt;, Bagus Setyoboedi&lt;sup&gt;1,*&lt;/sup&gt;, Citrawati D. K. Wungu&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Pediatrics, Universitas Airlangga, Dr. Soetomo General Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Biochemical Sciences, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agniya Ali Fahmi Hikmat</style></author><author><style face="normal" font="default" size="100%">Mia Ratwita Andarsini</style></author><author><style face="normal" font="default" size="100%">Bagus Setyoboedi</style></author><author><style face="normal" font="default" size="100%">Maria Christina Shanty Larasati</style></author><author><style face="normal" font="default" size="100%">Andi Cahyadi</style></author><author><style face="normal" font="default" size="100%">I Dewa Gede Ugrasena</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Risk Factors for Hepatotoxicity From L-Asparaginase Chemotherapy In Children With Acute Lymphoblastic Leukemia</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Acute lymphoblastic leukemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Children</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatotoxicity</style></keyword><keyword><style  face="normal" font="default" size="100%">L-asparaginase</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">January 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">921-927</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; L-asparaginase chemotherapy often causes hepatotoxicity and affects complete remission in pediatric acute lymphoblastic leukemia (ALL). This study aims to investigate the risk factors that affect the incidence of hepatotoxicity caused by L-asparaginase chemotherapy in ALL children. &lt;strong&gt;Methods:&lt;/strong&gt; An observational study with prospective sampling was conducted at Dr. Soetomo Hospital, Surabaya. The inclusion criteria included ALL children aged 1-18 years, undergoing ALL Induction phase chemotherapy based on the 2018 Indonesian Children's ALL protocol as evidenced by bone marrow aspiration, receiving L-asparaginase chemotherapy, and obtaining written consent from parents or guardians. Each child had 3 ml of blood drawn from a peripheral vein to assess their complete blood count, alanine transaminase (ALT) levels, and albumin level. &lt;strong&gt;Results:&lt;/strong&gt; Thirty-two children with ALL were collected. Two of them were excluded due to allergic reaction and enable to continue the L-asparaginase chemotherapy. Thirty of them were eligible participants. Approximately 53.3% of ALL children aged ≤ seven years. Fourteen (47%) children with ALL were included in the standard-risk group and 16 (53%) of them included high-risk group. There were significant differences in ALT levels between the four stages of observation (p=&amp;lt;0.001). Twenty-two ALL children had hepatotoxicity (73.3%), while 8 had non-hepatotoxicity (26.7%). Two risk factors had a significant influence on the occurrence of hepatotoxicity due to L-asparaginase chemotherapy including age and hypoalbuminemia (p=0.045, p=0.028). &lt;strong&gt;Conclusion:&lt;/strong&gt; Age and hypoalbuminemia were the risk factors that might affect the incidents of hepatotoxicity. Clinical monitoring before and after treatment needs to be done to prevent poor outcomes.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">921</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Agniya Ali Fahmi Hikmat&lt;sup&gt;1&lt;/sup&gt;, Mia Ratwita Andarsini&lt;sup&gt;1,2,*&lt;/sup&gt;, Bagus Setyoboedi&lt;sup&gt;1,2&lt;/sup&gt;, Maria Christina Shanty Larasati&lt;sup&gt;1,2&lt;/sup&gt;, Andi Cahyadi&lt;sup&gt;1,2&lt;/sup&gt;, I Dewa Gede Ugrasena&lt;sup&gt;1,2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Child Health, Faculty of Medicine Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Dr. Soetomo General Academic Teaching Hospital, Surabaya, East Java, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>